Exciting results from the Argus™ II Retinal Prosthesis System (‘Argus II’) clinical trial were presented today at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2011 Annual Meeting. The clinical trial included 30 subjects impla…
Author: Medical News Today
SAR 1118 Demonstrates Encouraging Results In Phase 2 Study Of Dry Eye Disease
SARcode Corporation presented data for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function …
Second Sight Announces Significant Results From The Argus™ II Retinal Prosthesis Trial At The ARVO 2011 Annual Meeting
Exciting results from the Argus™ II Retinal Prosthesis System (‘Argus II’) clinical trial were presented at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2011 Annual Meeting. The clinical trial included 30 subjects implanted i…
SAR 1118 Demonstrates Encouraging Results In Phase 2 Study Of Dry Eye Disease
SARcode Corporation presented data for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function …
Second Sight Announces Significant Results From The Argus™ II Retinal Prosthesis Trial At The ARVO 2011 Annual Meeting
Exciting results from the Argus™ II Retinal Prosthesis System (‘Argus II’) clinical trial were presented at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2011 Annual Meeting. The clinical trial included 30 subjects implanted i…
Why The Eye Is Better Than A Camera
The human eye long ago solved a problem common to both digital and film cameras: how to get good contrast in an image while also capturing faint detail…
Why The Eye Is Better Than A Camera
The human eye long ago solved a problem common to both digital and film cameras: how to get good contrast in an image while also capturing faint detail…
Statement From The American Academy Of Ophthalmology Regarding The Results Of The Comparison Of AMD Treatment Trials
Results of the Comparison of age-related macular degeneration (AMD) Treatment Trials (CATT), a study comparing bevacizumab (Avastin™) and ranibizumab (Lucentis™) in the treatment of neovascular or “wet” AMD, were released today by the National Eye …
Patient Group AMD Alliance International Responds To CATT Trials Research
Results of the Comparison of AMD Treatments Trials (CATT) study were published online today in The New England Journal of Medicine (NEJM). The CATT study was designed to compare two drugs currently used to treat wet-AMD: Lucentis (ranibizumab) and Avas…
Statement From The American Academy Of Ophthalmology Regarding The Results Of The Comparison Of AMD Treatment Trials
Results of the Comparison of age-related macular degeneration (AMD) Treatment Trials (CATT), a study comparing bevacizumab (Avastin™) and ranibizumab (Lucentis™) in the treatment of neovascular or “wet” AMD, were released today by the National Eye …
Patient Group AMD Alliance International Responds To CATT Trials Research
Results of the Comparison of AMD Treatments Trials (CATT) study were published online today in The New England Journal of Medicine (NEJM). The CATT study was designed to compare two drugs currently used to treat wet-AMD: Lucentis (ranibizumab) and Avas…
Retina Implant AG Presents Preliminary Results Of Permanently Implanted Patients At The ARVO Annual Meeting
Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced the presentation of initial findings from their second clinical trial. Results showed that the first seven patients who were permanently implanted …
Paulig Eye Surgery Centre First To Offer Innovative Keratoconus Treatment In Germany
The Paulig Eye Surgery Centre announces today that it has acquired advanced technology for performing Keraflex KXL, a new, non-invasive, non-surgical treatment for keratoconus. Surgeons at the Paulig Eye Surgery Centre will immediately begin treating p…
Bioptigen Offers Deep Imaging SDOCT For Pre-Clinical Applications
The medical imaging device company, Bioptigen Inc., has created the commercial market’s deepest spectral domain optical coherence tomography (SDOCT) imaging system for pre-clinical applications. Called the Envisu R4300, it is the first Fourier-domain O…
Genetic Clue To ‘Emergency’ Glaucoma
Jackson Laboratory researchers and their collaborators have reported their discovery of a gene implicated in an acute and severe form of glaucoma known as angle-closure glaucoma (ACG). The gene’s activity points to previously unsuspected mechanisms inv…
Positive Ellex 2RT Data Demonstrates Efficacy In Treatment Of Early AMD
Ellex Medical Lasers Limited (ASX:ELX), a global leader in ophthalmic technology, today announced milestone clinical results for its breakthrough Retinal Regeneration Therapy (Ellex 2RT™) for the treatment of Early Age-Related Macular Degeneration (A…
Avastin Vs Lucentis: A Cheaper Drug To Treat Blindness Revealed
Simply stated, macular degeneration is the most common cause of age related blindness. This week, it seems that there may be a cheaper medical alternative that previously thought as a new report states that both brand names Lucentis and Avastin are eq…
Gene Therapy Shows Promise Against Age-Related Macular Degeneration
A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration (AMD), according to a new in vivo study by researchers at Tufts University School of Medicine…
Bioptigen Unveils Image Analysis Software
Bioptigen Inc., a medical device company whose innovative ophthalmic imaging technologies produce highly resolved images for researchers and clinicians, has released a new software package, InVivoVue™Miner. InVivoVueMiner automates analysis of retina…
Avastin And Lucentis Are Equally Effective In Treating Age-Related Macular Degeneration: NIH Study
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and …